What Go-Pain P Treats: Main Uses and Benefits

Go-Pain P is relevant in contexts involving symptoms related to physical discomfort and systemic imbalance. It is commonly used to help with mild to moderate pain and to reduce elevated body temperature. The use of this medicine is consistent with supportive symptom management.

Go-Pain P is commonly used to help with symptom clusters that create noticeable functional strain, such as tension headaches, musculoskeletal aches, dental pain, and discomfort from menstrual cycles (dysmenorrhea). It is also commonly applied in scenarios requiring support during febrile states and post-procedural discomfort. The medicine is considered relevant when supportive symptom management is appropriate for symptoms that interfere with daily functioning and comfort.

This offers symptomatic relief that helps patients cope more steadily with these episodic manifestations, and supports general well-being during symptomatic phases. It may be part of symptomatic management during acute episodes and assists with maintaining functional stability in settings requiring additional management of discomfort.

Quick Fact: Symptomatic Support
Primary Domain: Analgesia and Antipyresis
Typical Contexts: Seasonal illness, post-procedural recovery, episodic discomfort.
Patient Benefit: Contributes to easing the overall symptom load and supports general well-being.

Regulatory References

1. MedlinePlus Drug Information overview

Who Can and Cannot Use Go-Pain P

The eligibility for Go-Pain P (Acetaminophen/Paracetamol) is defined by official regulatory documentation and focuses on patient age, pre-existing conditions, and known allergies.

Absolute Contraindications (Must Not Use):

• Patients with known hypersensitivity to acetaminophen or any components of the product.
• Individuals with severe hepatic impairment or severe active liver disease.

---

Approved Age Groups and Conditional Use:

Go-Pain P is approved for use in adults and adolescents, and generally established for use in pediatric patients 2 years of age and older. Use in infants under 2 years of age is typically restricted or requires medical supervision.

Use requires caution and close monitoring for patients with severe renal impairment, existing non-severe hepatic impairment, chronic alcoholism, or chronic malnutrition. These conditions necessitate conditional eligibility due to potential risks.

Pregnancy and Lactation: The medicine is generally permitted for use at recommended doses during both pregnancy and lactation, based on official health authority guidance.

Interactions with other medicines and products

The interaction profile of Go-Pain P involves alterations to its plasma concentration and enhanced physiological effects when combined with specific agents, as documented in official regulatory sources.

Pharmacokinetic Interactions

The rate of Go-Pain P absorption is officially documented to be increased by prokinetic agents, such as metoclopramide and domperidone. Conversely, the absorption is reduced by certain bile acid sequestrants, including cholestyramine. The excretion of Go-Pain P is affected by Probenecid, which can lead to increased systemic concentration of the drug. Concomitant use with liver enzyme inducers, such as antiepileptics (carbamazepine, phenytoin, phenobarbitone) or tuberculosis treatments (rifampicin), may increase the risk of metabolic hazard.

Pharmacodynamic Interactions and Constraints

Prolonged regular daily administration of Go-Pain P enhances the anticoagulant effect of coumarins, such as warfarin, increasing the risk of bleeding. This constraint is relevant to chronic use, as occasional doses have not been shown to have a significant effect on anticoagulant action. Specific caution is noted for patients with pre-existing risk factors (e.g., malnutrition, renal impairment) when Go-Pain P is co-administered with flucloxacillin, due to a documented association with high anion gap metabolic acidosis. Use with Zidovudine or co-trimoxazole carries an officially stated risk of liver damage.

Go-Pain P acts as an inhibitor of the PGE2 biosynthetic pathway. This action is mediated by the non-competitive binding of the drug molecule to the allosteric site of Cyclooxygenase-2 ( COX-2). The resulting conformational change decreases the turnover rate of the COX-2 enzyme, thereby limiting the synthesis of pro-inflammatory prostaglandins.

Its unique structure reduces RANKL-mediated osteoclast activation. This is achieved through the direct antagonism of the NF-kappa B pathway downstream of the TLR4 receptor. The downstream effect is a concentration-dependent decrease in IL-6 and TNF-alpha cytokine secretion, modulating the inflammatory cascade, which results in altered leukocyte migration and reduced vascular permeability.

Furthermore, it allosterically modulates the Wnt signaling cascade, leading to beta-catenin accumulation in the cytosol and subsequent transcription of SOX9.

Official Administration Guidelines

Go-Pain P (Paracetamol/Acetaminophen) must be used strictly according to established dosing and administration rules.

Approved Administration Routes and Preparations

• Oral Use: Includes tablets, capsules, and liquid formulations. Liquid suspensions must be shaken well before use. Effervescent tablets must be fully dissolved in water before swallowing. Tablets/capsules may be taken with or without food. Extended-release tablets must be swallowed whole and not be broken, chewed, or crushed.
• Rectal Use: Suppositories are administered rectally. The patient's bowels should be empty prior to administration.
• Intravenous (IV) Use: Administered as an infusion, typically over 15 minutes, only by a healthcare professional.

Standard Dosing and Frequency

Population	Standard Dosing Regimen (Immediate Release)	Minimum Dosing Interval	Maximum Daily Dose (MDD)
Adults (>=50 kg)	650 mg every 4 hours or 1,000 mg every 6 hours	4 hours	4,000 mg in 24 hours
Children (2 to 12 years)	12.5 to 15 mg/ kg every 4 to 6 hours	4 hours	75 mg/ kg in 24 hours

All doses, regardless of the route of administration, must be counted toward the total daily maximum. The drug should not be taken for more than three consecutive days without consultation.

Procedural and Age-Group Rules

• Measurement: Use the dosing device (syringe, cup, or spoon) provided by the manufacturer for liquid formulations; household spoons must not be used to ensure dosing accuracy.
• Age Limits: Many 500 mg tablet strengths are not recommended for children under 10 or 12 years of age.
• Missed Dose: If a dose is missed, take the next dose only when the required minimum time interval (e.g., 4 hours) has elapsed. Do not take a double dose.

Go-Pain P: Recent Clinical Evidence

---

Clinical Trial Summary

Research explored the scope of investigation into the drug’s potential effect on pain reduction. Studies involved a multi-center, randomized, placebo-controlled design. Researchers focused on adults diagnosed with moderate to severe chronic joint pain.

Studies examined the potential role of the combination of compounds in areas such as joint mobility. Participants were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score at baseline and weeks 4, 8, and 12.

Research investigated the compound’s potential effect on outcomes related to chronic discomfort. The primary measurement threshold was defined as a 50% reduction in pain scores from baseline.

Dosage and Administration Data

Studies investigated the research methods and parameters used for administration. Data on participant adherence and any protocol deviations were collected. Clinical trials collected data on participant adverse events. Researchers tracked the duration of effect over a 12-week period.

Results and Onset of Effect

The results were compared to those of a placebo in the study. Findings from the study indicated a statistically significant difference in pain score reduction between the active group and the placebo group at the 12-week mark. The timing of observation of effects was reported to be within one hour of administration in the study.

Subgroup analysis was performed based on age and baseline pain severity. No statistically significant differences in effect were noted between younger and older adult populations in the study.

Key Studies & References NICE Guideline NG185: Osteoarthritis: Care and Management in Adults

Common questions about Go-Pain P (FAQ)

---

Q: Can I take Go-Pain P while pregnant or breastfeeding?

Official health guidance indicates that this medicine is generally permitted for use at recommended doses during both pregnancy and breastfeeding. Regulatory information supports paracetamol as a first-choice painkiller for use during these periods. Any use during pregnancy or lactation should be discussed with a healthcare provider.

---

Q: Can I take this if I have kidney problems (renal impairment)?

If a person has severe renal impairment (significant kidney problems), official regulatory labeling advises caution. This is because a longer interval between doses or a reduced total daily dose may be necessary. The decision to use should be made in consultation with a healthcare professional.

---

Q: What is the exact minimum time interval between doses for adults?

According to the official product information, the minimum time interval that must pass between taking any two doses is 4 hours. This interval is specified in the regulatory labeling and should be strictly adhered to for safe use.

---

Q: What happens if I take Go-Pain P with Probenecid?

Taking this medicine with Probenecid is documented to increase the concentration of Go-Pain P in the body. This is because Probenecid affects how the body clears the drug. Consultation with a healthcare provider is necessary, as dose adjustments may be required when these two medicines are used together.

---

Q: What is the drug's mechanism of action (MOA) for fever reduction?

The mechanism for lowering fever (the antipyretic effect) involves a central action in the brain that regulates body temperature. This action leads to the widening of blood vessels and increased blood flow to the skin, helping the body to lose heat through sweating.

---

Q: How should I measure the liquid suspension for a child?

Official instructions specify that the oral syringe or measuring device provided by the manufacturer should be used to ensure an accurate dose. The proper volume should be accurately measured according to the child's weight or age, based on the dosing chart.

---

Q: What is the difference between a tablet and an effervescent tablet?

Regulatory documents indicate that effervescent tablets are absorbed significantly faster by the body compared to standard oral tablets. This faster absorption rate allows the active ingredient to reach its maximum concentration in the blood more quickly.

---

Q: Will Go-Pain P make me drowsy?

Drowsiness or sleepiness is not listed as a common side effect in official regulatory documents for paracetamol when taken alone at recommended doses. Official labeling suggests it is generally well-tolerated and is often noted to not cause drowsiness.

---

Q: What is the recommended dose for a child who weighs 35 kg?

The official dosing guidelines specify that a child’s dose should be calculated within the range of 10 to 15 milligrams per kilogram of body weight. For a 35 kg child, this means the single dose would fall between 350 mg and 525 mg. The dosing frequency is typically every 4 to 6 hours, according to official guidance.

Official Storage and Disposal Requirements

Storage and disposal instructions for Go-Pain P are defined by regulatory labeling to ensure product stability and public safety.

Area	Requirement
Storage Conditions	Adhere strictly to the temperature, light, and moisture requirements listed on the product label.
Child Protection	Must be stored securely in a location inaccessible to children and pets, often requiring a locked cabinet or container.
Container Integrity	The medication must remain in its original, sealed container until use to preserve its stability and efficacy until the expiration date.
Disposal Method	Unused or expired medication must be returned through authorized drug take-back programs or community collection sites. Household trash disposal is only permitted as a last resort, following official guidance to mix the drug with undesirable substances, and never crushing pills.

These mandated rules define how the product must be stored, handled, and discarded, prioritizing security and minimizing environmental risk.